Although the comparison groups were small (n = 6–10 each) and SGLT2 inhibitors were prescribed for clinical indications, the study observations provide detailed molecular information at the cellular level in the human kidney according to diabetes status and SGLT2 inhibitor use. The gene discussed is SLC5A2; the disease is diabetes mellitus.